| 1JK Stock | | | EUR 31.28 0.82 2.55% |
CFO
Timothy Sullivan is Chief Financial Officer, Treasurer of APELLIS PHARMACTDL 0001 since 2017.
| Age | 48 |
| Tenure | 7 years |
| Phone | 617 977 5700 |
| Web | http://www.apellis.com |
APELLIS PHARMACTDL Management Efficiency
The company has return on total asset
(ROA) of
(0.4647) % which means that it has lost $0.4647 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(5.0711) %, meaning that it generated substantial loss on money invested by shareholders. APELLIS PHARMACTDL's management efficiency ratios could be used to measure how well APELLIS PHARMACTDL manages its routine affairs as well as how well it operates its assets and liabilities.
APELLIS PHARMACTDL 0001 has accumulated 409.63
M in total debt with debt to equity ratio
(D/E) of 7.94, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. APELLIS PHARMACTDL 0001 has a current ratio of 4.07, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist APELLIS PHARMACTDL until it has trouble settling it off, either with new capital or with free cash flow. So, APELLIS PHARMACTDL's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like APELLIS PHARMACTDL 0001 sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for APELLIS to invest in growth at high rates of return. When we think about APELLIS PHARMACTDL's use of debt, we should always consider it together with cash and equity.
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. APELLIS PHARMACT operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 445 people. APELLIS PHARMACTDL 0001 (1JK) is traded on Frankfurt Exchange in Germany and employs 767 people.
Management Performance
APELLIS PHARMACTDL 0001 Leadership Team
Elected by the shareholders, the APELLIS PHARMACTDL's board of directors comprises two types of representatives: APELLIS PHARMACTDL inside directors who are chosen from within the company, and outside directors, selected externally and held independent of APELLIS. The board's role is to monitor APELLIS PHARMACTDL's management team and ensure that shareholders' interests are well served. APELLIS PHARMACTDL's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, APELLIS PHARMACTDL's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Sullivan, Chief Financial Officer, Treasurer | |
| Nicole Perry, Vice President - Finance | |
| Adam Townsend, Chief Commercial Officer | |
| Alec Machiels, Independent Director | |
| Thomas Lackner, Senior Vice President Head of Europe | |
| Paul Fonteyne, Independent Director | |
| A Dunlop, Independent Director | |
| Stephanie OBrien, Independent Director | |
| Cedric Francois, President, Chief Executive Officer, Co-Founder, Director | |
| Gerald Chan, Independent Chairman of the Board | |
| David Watson, General Counsel, Vice President of Corporate Development | |
| Victoria Brown, Senior Vice President Program Team Lead – Systemic Chronic | |
| Pascal Deschatelets, Co-Founder, Chief Operating Officer | |
| Federico Grossi, Chief Medical Officer | |
| Lukas Scheibler, Chief Innovation Officer | |
APELLIS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is APELLIS PHARMACTDL a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in APELLIS Stock
APELLIS PHARMACTDL financial ratios help investors to determine whether APELLIS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in APELLIS with respect to the benefits of owning APELLIS PHARMACTDL security.